The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 15, 2004, Pages 4027-4030

  Smith, Garrick ^a   Ruhland, Thomas ^a   Mikkelsen, Gitte ^a   Andersen, Kim ^a   Christoffersen, Claus Tornby ^a   Alifrangis, Lene Hjorth ^a   Mørk, Arne ^a   Wren, Stephen P ^b   Harris, Neil ^b   Wyman, Barry M ^b   Brandt, Guillaume ^b  

^a H LUNDBECK A S   (Denmark)

^b Argenta Discovery Ltd   (United Kingdom)

Author keywords

Glycine transporter inhibitors; NMDA dysfunction; Schizophrenia

Indexed keywords

4 [5 CHLORO 2 (4 METHOXYPHENYLSULFANYL)PHENYL] 2 METHYLPIPERAZIN 1 YLACETIC ACID; ACETIC ACID DERIVATIVE; GLYCINE DERIVATIVE; GLYCINE TRANSPORTER 1 INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HIPPOCAMPUS; IC 50; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; PROTEIN MOTIF; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ACETIC ACIDS; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; ANTIPSYCHOTIC AGENTS; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HIPPOCAMPUS; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PIPERAZINES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042691500     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.043     Document Type: Article

References (11)

1. Coyle J.T., Goff J.T. Am. J. Psychiat. 158:2001;1367-1377
2. Heresco-Levy U. Int. J. Neurospsychopharm. 3:2000;243-258
3. Slassi A., Egle I. Expert Opin. Ther. Patents. 14:2004;201-214
4. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15730-15734
5. Tsai G., Lane H.-Y., Yang P., Chong M.-Y., Lange N. Biol. Psychiat. 55:2004;452-456
6. Brown A., Carlyle I., Clark J., Hamilton W., Gibson S., McGarry G., McEachen S., Rae D., Thorn S., Walker G. Bioorg. Med. Chem. Lett. 11:2001;2007-2009
7. Atkinson B.N., Bell S.C., De Vivo M., Kowalski L.R., Lechner S.M., Ognyanov V.I., Tham C.-S., Tsai C., Jia J., Ashton D., Klitenick M.A. Mol. Pharm. 60:2001;1414-1420
8. Ruhland T., Bang K.S., Andersen K. J. Org. Chem. 67:2002;5257-5268
9. 3H-glycine was added, and the cells were incubated for 15 min. The cells were washed twice in HBS. Scintillation fluid was added, and the plates were counted on a Trilux (Wallac) scintillation counter
10. NAR reaction with 2-fluoronitrobenzene (method b), and the resulting product was subjected to catalytic hydrogenation at 1.5 bar using Pd/C in methanol for removal of the benzyl group. The 2R, 5R- and 2S, 5S-dimethyl piperazines were prepared by borane mediate reduction of the commercially available diketopiperazines, cyclo-L-ala-L-ala and cyclo-D-ala-D-ala as described by:
11. Jung M.E., Rohloff J.C. J. Org. Chem. 50:1995;4909-4913. followed by monobenzylation and then used as described for the trans stereoisomers